Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health (Nasdaq: AWH) has signed an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University Lodz to develop a high-risk early detection test for ovarian cancer using novel microRNA technology. This collaboration aims to enhance early detection, which significantly increases survival rates, as ovarian cancer has a high mortality rate. The initiative reflects Aspira's commitment to women's health and creating innovative testing options, particularly in assessing ovarian cancer risk.

Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its financial results for Q4 and full year 2020 on March 25, 2021, after market close. An investor conference call and webcast is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative testing options in women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its FDA-cleared products OVA1® and OVERA® assist in evaluating ovarian malignancy risk. Aspira is committed to improving gynecologic health outcomes and addressing ethnic disparities in healthcare.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced its subsidiary, Aspira Labs, has achieved credentialing with New York State’s Medicaid program, covering an estimated 6.5 million lives starting April 1, 2021. This credentialing expands the total covered lives for Aspira's OVA1® test to 179 million nationwide, enhancing access for ovarian cancer risk assessment. Aspira Labs is now credentialed in the top 9 U.S. states by Medicaid population, totaling nearly 60 million lives. The company aims to address health disparities in ovarian cancer risk detection.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced the appointment of Ms. Nicole Sandford to its Board of Directors. With extensive experience in regulatory leadership and corporate governance, Sandford is expected to play a crucial role in the company's growth. She previously served at Deloitte and is passionate about improving women’s health, particularly in ovarian cancer. Sandford aims to leverage her skills to aid Aspira in achieving its mission. Aspira focuses on innovative testing solutions for gynecologic health and is known for its FDA-cleared products, OVA1 and OVERA.

Aspira Women's Health Inc. (Nasdaq: AWH) emphasizes its commitment to mitigating racial disparities in ovarian cancer risk assessment during Black History Month. The company aims to enhance testing access for women of all backgrounds, particularly those at high risk. Notably, Black women face significantly lower 5-year survival rates—36% compared to 46% for White women. Aspira's product OVA1plus is designed to improve risk detection in Black women through its advanced multi-biomarker algorithm. CEO Valerie Palmieri highlights the urgent need for equitable healthcare solutions.

Aspira Women's Health, Inc. (Nasdaq: AWH) announced its participation in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference happening from February 17-19. The company will present on February 18 at 9:30 am Eastern Time. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment. Their product portfolio includes FDA-cleared tests like OVA1® and OVERA®, and they aim to address ethnic disparities in health outcomes. For more details, visit www.aspirawh.com.

Aspira Women’s Health (Nasdaq: AWH) announced the integration of National Comprehensive Cancer Network® (NCCN®) management recommendations into its Aspira GenetiX Clinical reports. This personalized hereditary cancer genetic risk testing service focuses on gynecologic cancers such as endometrial, ovarian, and cervical cancers. The inclusion of NCCN guidelines strengthens the product's position in the market and enhances support for healthcare providers managing high-risk patients.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced a public offering of 6,000,000 shares at $7.50 per share, with a potential increase of 900,000 shares via underwriter option. The offering, managed by William Blair & Company and Truist Securities, aims to raise approximately $45 million, potentially $51.75 million if the option is fully exercised. Funds will support sales, marketing, working capital, and R&D. The offering is set to close on February 8, 2021. The shares are offered under an effective shelf registration statement with the SEC.

Aspira Women’s Health Inc. (Nasdaq: AWH) has initiated an underwritten public offering of its common stock, with market conditions influencing its completion. The offering will include a 30-day underwriter option for an additional 15% of shares. Proceeds are intended for sales and marketing, working capital, strategic hires, product expansion, and potential acquisitions. The offering is backed by a previously filed shelf registration statement with the SEC, though no specific commitments for acquisitions are currently in place.